Assessment of cancer therapy‐related cardiac dysfunction in breast cancer women using a new speckle tracking echocardiography index: The GAVS

Abstract

AbstractBackgroundRecently, peak atrial longitudinal strain (PALS) has emerged as a possible predictor of Cancer therapy‐related cardiac dysfunction (CTRCD) in cancer patients (CP), in addition to left ventricular global longitudinal strain (GLS). Thus, considering the link between left atrium and left ventricle, the aim of this study was to assess the global atrio‐ventricular strain (GAVS) in CP, to detect early cardiotoxicity.MethodsA prospective study was carried out enrolling 131 breast cancer women (mean age 51.4 ± 10.4 years) receiving anti‐cancer treatment. Clinical and echocardiographic evaluation was performed at baseline (T0), 3 (T1), 6 (T2) and 12 months (T3) after starting treatment. CTRCD was defined according to the 2022 ESC Cardio‐Oncology guidelines.ResultsForty‐four patients developed CTRCD (3 moderate and 41 mild CTRCD group A) and 87 patients did not (group B). In group A, significant changes in GLS, PALS, GAVS, LASi (left atrial stiffness index) and LVEF/GLS occurred earlier than LVEF, that reduced significantly only at T3 (p‐value < .05). Significant changes in LASi, PALS and GAVS occurred even in group B but reduction in GAVS (−21% vs. −5%) and PALS (−24% vs. −12%) was significantly greater in group A compared to group B (p‐value = .04).ConclusionsOur study confirms high sensitivity of speckle tracking echocardiography in detecting subclinical myocardial damage in CP and the usefulness of a multiparametric echocardiographic evaluation including PALS and GLS (GAVS) for having a global evaluation of the phenomenon cardiotoxicity.